Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization.
Brief Summary: Chronic hepatitis B (CHB) infection is complicated by cirrhosis and liver cancer. In Thailand, 7% of adults are chronically infected by Hepatitis B virus (HBV). The risk of perinatal transmission of HBV is about 12% when a mother has a high HBV load in her plasma, even if her infant receive specific immunoglobulin and vaccine.

The hypothesis of this study is that a potent antiviral, tenofovir, can decrease HBV load in HBV infected pregnant women and therefore reduce the risk of perinatal transmission/ Pregnant women participating in this study will receive tenofovir or placebo during the last trimester of pregnancy and two months postpartum. The risk of perinatal transmission will be compared between the two groups.

The results of the study will help define policy to manage HBV infected pregnant women to prevent perinatal transmission.


Options:
A: Arm Label: Tenofovir disoproxil fumarate; Type: EXPERIMENTAL; Interventions: Drug: tenofovir disoproxil fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tenofovir disoproxil fumarate; Assigned to Arm(s): Tenofovir disoproxil fumarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: E/C/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: E/C/F/TAF | Arm Label: Stay on Baseline Treatment Regimen (SBR); Type: ACTIVE_COMPARATOR; Interventions: Drug: E/C/F/TDF, Drug: EFV/FTC/TDF, Drug: RTV, Drug: ATV, Drug: FTC/TDF, Drug: COBI | Intervention Type: DRUG; Name: E/C/F/TAF; Assigned to Arm(s): E/C/F/TAF | Intervention Type: DRUG; Name: E/C/F/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: EFV/FTC/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: RTV; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: ATV; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: FTC/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: COBI; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR)
C: Arm Label: Blinded Phase: B/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF, Drug: ABC/DTG/3TC Placebo | Arm Label: Blinded Phase: ABC/DTG/3TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABC/DTG/3TC, Drug: B/F/TAF Placebo | Arm Label: Open-Label Phase; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF | Intervention Type: DRUG; Name: ABC/DTG/3TC; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC | Intervention Type: DRUG; Name: B/F/TAF; Assigned to Arm(s): Blinded Phase: B/F/TAF, Open-Label Phase | Intervention Type: DRUG; Name: ABC/DTG/3TC Placebo; Assigned to Arm(s): Blinded Phase: B/F/TAF | Intervention Type: DRUG; Name: B/F/TAF Placebo; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC
D: Arm Label: Antepartum Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zidovudine (ZDV), Drug: Nevirapine (NVP): Antepartum Mothers, Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail, Drug: Nevirapine (NVP): Infant short-course | Arm Label: Antepartum Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine-Zidovudine (3TC-ZDV), Drug: Lopinavir-ritonavir (LPV-RTV), Drug: Nevirapine (NVP): Infant short-course | Arm Label: Antepartum Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lopinavir-ritonavir (LPV-RTV), Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]), Drug: Nevirapine (NVP): Infant short-course | Arm Label: Late Presenters; Type: OTHER; Interventions: Other: No Intervention | Arm Label: Postpartum Arm A (Maternal Prophylaxis); Type: EXPERIMENTAL; Interventions: Drug: Lopinavir-ritonavir (LPV-RTV), Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]), Drug: Nevirapine (NVP): Infant short-course | Arm Label: Postpartum Arm B (Infant Prophylaxis); Type: EXPERIMENTAL; Interventions: Drug: Nevirapine (NVP): Infant extended | Arm Label: Maternal Health Arm A (Continue triple ARVs); Type: EXPERIMENTAL; Interventions: Other: Continue triple ARVs | Arm Label: Maternal Health Arm B (Discontinue triple ARVs); Type: ACTIVE_COMPARATOR; Interventions: Other: Discontinue triple ARVs | Intervention Type: DRUG; Name: Zidovudine (ZDV); Assigned to Arm(s): Antepartum Arm A | Intervention Type: DRUG; Name: Nevirapine (NVP): Antepartum Mothers; Assigned to Arm(s): Antepartum Arm A | Intervention Type: DRUG; Name: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Assigned to Arm(s): Antepartum Arm A | Intervention Type: DRUG; Name: Lamivudine-Zidovudine (3TC-ZDV); Assigned to Arm(s): Antepartum Arm B | Intervention Type: DRUG; Name: Lopinavir-ritonavir (LPV-RTV); Assigned to Arm(s): Antepartum Arm B, Antepartum Arm C, Postpartum Arm A (Maternal Prophylaxis) | Intervention Type: DRUG; Name: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Assigned to Arm(s): Antepartum Arm C, Postpartum Arm A (Maternal Prophylaxis) | Intervention Type: DRUG; Name: Nevirapine (NVP): Infant short-course; Assigned to Arm(s): Antepartum Arm A, Antepartum Arm B, Antepartum Arm C, Postpartum Arm A (Maternal Prophylaxis) | Intervention Type: DRUG; Name: Nevirapine (NVP): Infant extended; Assigned to Arm(s): Postpartum Arm B (Infant Prophylaxis) | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Late Presenters | Intervention Type: OTHER; Name: Discontinue triple ARVs; Assigned to Arm(s): Maternal Health Arm B (Discontinue triple ARVs) | Intervention Type: OTHER; Name: Continue triple ARVs; Assigned to Arm(s): Maternal Health Arm A (Continue triple ARVs)

Answer: A